Amylyx Corp (AMLX) Price to Earnings Ratio
The current price-to-earnings valuation allows for an analysis of investments in the neuroprotective developments of Amylyx Pharmaceuticals (AMLX). The company relies on its scientific potential in treating brain degeneration by creating combination therapies to protect neurons. However, the recall of its primary drug wiped out market advantages, necessitating an R&D restart. The latest parameter stands at -24.00, reflecting the order book's reaction to current capitalization risks.
Analytical breakdowns for Amylyx Pharmaceuticals, Inc. (AMLX)
- price and consensus price forecast:
- market capitalization details:
- balance sheet equity data:
- debt obligations and liquidity statistics:
Debt to Capital Amylyx Pharmaceuticals|AMLX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Ratio Amylyx Pharmaceuticals, Inc.|AMLX - Company Total Debt|Debt to Net Assets Ratio Amylyx|AMLX - Company Long-Term Debt|Current Liabilities Amylyx Pharmaceuticals|Intermediate Coverage Ratio amylyx.com
- business earnings and investment ratios data:
AMLX - Net Profit|Projected Future Earnings Amylyx Pharmaceuticals|AMLX - Price to Earnings Ratio|Future Price to Earnings Multiple Amylyx Corp|AMLX - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Amylyx Pharmaceuticals Inc|AMLX - Operating profit EBITDA|Net earnings per share (EPS TTM) Amylyx Pharmaceuticals|AMLX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months amylyx.com|AMLX - Earnings growth in current year|Expected net earnings per share growth next year Amylyx Pharmaceuticals
- sales volume and revenue indicators:
General company analysis:Amylyx Pharmaceuticals Inc - AMLX
To find a fundamental floor, it is essential for an investor to evaluate the business value via the price-to-earnings ratio, which allows for the identification of undervalued assets and prevents overpaying for a fading business. By analyzing the quarterly P/E of Amylyx Pharmaceuticals (AMLX), one can compare market expectations with the actual commercialization efficiency of ALS therapy and the potential of the drug RELYVRIO, thereby determining the reliability of investments in the biotech sector.
Analysis of competing companies
Price to Earnings Ratio BIIB|P/E Multiple NBIX|Regencell (RGC) - Market Cap to Net Income Ratio|Price to Earnings Ratio axsome.com AXSM|P/E Multiple ACADIA Pharmaceuticals ACAD|XENE - Price to Earnings Ratio|Business Payback Period Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Price to Earnings Ratio|CPRX (Catalyst Pharmaceuticals) - Price to Earnings Ratio|DNLI (denalitherapeutics.com) - P/E Multiple|Price to Earnings Multiple HRMY (Harmony Biosciences Holdings, Inc.)|P/E Multiple BHVN|Market Price to Net Income Ratio TRVI|Price to Earnings Ratio Praxis Precision Medicines, Inc. PRAX|Anavex Corp - Price to Earnings Ratio|CBLL: Price to Earnings Ratio|Company Value to Net Income PRTA (prothena.com)|Alector, Inc. (ALEC) - Price to Earnings Ratio|Price to Earnings Multiple ANNX|Price to Earnings Ratio Omeros Corp.|Neurogene Therapeutics (NGNE) - Business Payback Period|P/E Multiple ACIU|VYGR (Voyager Therapeutics) - Company Value to Net Income|P/E Multiple NMRA (neumoratx.com)|SCLX: Price to Earnings Multiple|TVGN - Price to Earnings Ratio|Market Cap to Earnings Alpha Cognition Inc.|CGTX: P/E Multiple|inhibikase.com (IKT) - P/E Multiple|Price to Earnings Ratio Cassava Sciences Inc|ASRT - Market Cap to Net Income Ratio|Price to Earnings Ratio Coya (COYA)|P/E Multiple VistaGen Therapeutics Inc (VTGN)|Ovid Therapeutics Inc. - Price to Earnings Ratio|Business Payback Period Acumen Pharmaceuticals (ABOS)|CervoMed Corporation - P/E Multiple|Business Payback Period alteritytherapeutics.com ATHE|CLNN: P/E Multiple|Market Cap to Earnings PepGen Corp (PEPG)|Price to Earnings Ratio Jupiter Neurosciences, Inc.|RLMD: Company Value to Net Income|P/E Multiple ANVS|Price to Earnings Ratio Grace Tx GRCE|Price to Earnings Ratio Firefly Neuroscience, Inc AIFF|KLTO: Price to Earnings Multiple|NRSN - Price to Earnings Ratio|RVPH: Price to Earnings Ratio|MTVA (MetaVia Inc.) - Price to Earnings Ratio|NeurAxis Inc. (NRXS) - P/E Multiple|Price to Earnings Ratio Helius Medical|Passage Bio, Inc. - Market Cap to Net Income|Price to Earnings Ratio NEUP (Neuphoria)|NERV - Market Cap to Earnings|P/E Multiple ATHA (athira.com)|P/E Multiple Addex Therapeutics Ltd ADXN|Alzamend Neuro, Inc. - P/E Multiple|CYCN - P/E Multiple|PTIX (Protagenic Therapeutics, Inc.) - Price to Earnings Ratio|Market Cap to Earnings Pasithea (KTTA)|Price to Earnings Ratio Cortigent|Market Cap to Earnings Avenue Therapeutics Inc. ATXI|Price to Earnings Ratio brainstorm-cell.com (BCLI)|Price to Earnings Ratio Cara Therapeutics, Inc CARA|P/E Multiple CHRO (chromocell.com)|Company Value to Net Income ELYM|Intra-Cellular Therapies Inc. - P/E Multiple|Market Cap to Earnings Longboard Pharmaceuticals Inc|Marinus (MRNS) - Price to Earnings Ratio|NKGN - Business Payback Period|Price to Earnings Ratio NeuroBo Pharmaceuticals|SAGE: Company Value to Net Income|P/E Multiple SNPX|Trevena Inc. - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Price to Earnings Ratio|Cerevel Therapeutics - P/E Multiple
